Skip to main content
Clinical Trials/NCT07401797
NCT07401797
Recruiting
Not Applicable

Specimens for Lung Cancer Panel Design

Maverix Medical1 site in 1 country2,000 target enrollmentStarted: August 7, 2024Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Maverix Medical
Enrollment
2,000
Locations
1
Primary Endpoint
Test performance

Overview

Brief Summary

This is an observational study designed to determine the optimal combination of biomarkers and clinical data for the early detection, confirmation, and better treatment of lung cancer including minimizing recurrence.

Detailed Description

Peripheral venous blood and clinical data will be collected from consented subjects with lung nodules identified in radiology that are suspicious for lung cancer before invasive diagnosis or treatment is initiated. Various analyses will be conducted to determine which subset of biomarkers is most likely to be the most useful in the clinic. Attributes considered are accuracy (sensitivity, specificity, improvement over other methods) and ease of collection and transport. Results will not be reported to treating physicians and will not alter care of the patient.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery.
  • The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months.
  • Ability to understand the study and sign an informed consent form
  • Relevant clinical data accessible
  • Ability and willingness to safely donate 40 mL of blood
  • Ability of the site to collect and process blood per protocol Exclusion
  • 1\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater.
  • 2\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary.
  • 3\. Previous cancer diagnosis of any origin.
  • Is currently pregnant

Exclusion Criteria

  • Not provided

Arms & Interventions

Prior cancer

Prior cancer history

No prior cancer

Indeterminant lung nodules with no prior history of cancer

Healthy volunteers

Healthy volunteers

Outcomes

Primary Outcomes

Test performance

Time Frame: Two years from final case enrollment

Analytical validity, clinical validity, and clinical utility. Ability to correctly re-risk indeterminate nodules and ability to change clinical care based on hypothetical treatment plans for different test outcomes. Actual test results will not be provided to physicians, and actual care will not be affected.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Maverix Medical
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials